PatentJul 28, 2026, 07:36 AM
Kazia Therapeutics Files Provisional Patent for TNBC Metastatic Recurrence
AI Summary
Kazia Therapeutics has filed a provisional patent application for a novel therapeutic strategy aimed at preventing metastatic recurrence in patients with high-risk early-stage triple-negative breast cancer (TNBC). This filing is supported by new preclinical findings where adjuvant paxalisib reduced residual disease and local recurrence by 95% and lung metastatic burden by 40%. Complementary translational studies showed paxalisib completely disrupted 100% of circulating tumor cell clusters. The company plans to evaluate opportunities to expand paxalisib's clinical development into earlier-stage TNBC.
Key Highlights
- Filed a provisional patent application for a novel strategy to prevent metastatic recurrence in TNBC.
- Preclinical data showed adjuvant paxalisib reduced residual disease and local recurrence by 95% (p<0.0001).
- Adjuvant paxalisib also reduced lung metastatic burden by 40% (p<0.027) in preclinical models.
- Translational studies demonstrated paxalisib completely disrupted 100% of circulating tumor cell clusters.
- The strategy targets high-risk early-stage triple-negative breast cancer (TNBC).
- Company is evaluating opportunities to broaden paxalisib's clinical development into earlier-stage TNBC.
Price Impact
More from KZIA